Physician profile
Ivan Cardona
NPI 1215038088
$8,782.85
in general payments reported to CMS, 2019-2025
34 companies · $3,052 in 2025
The $3,052 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $229 · 2021: $903 · 2022: $1,332 · 2023: $1,016 · 2024: $1,512 · 2025: $3,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,430 · Education: $124 · Consulting Fee: $25.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,430.46 |
| Education | $123.99 |
| Consulting Fee | $25.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,726.97 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,079.91 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $822.28 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $693.80 | 2019-2025 | Nucala |
| Csl Behring | $570.34 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Pharming Healthcare, INC. | $543.62 | 2019-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $450.06 | 2021-2025 | |
| Pfizer INC. | $387.98 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.85 | 2021-2025 | Cuvitru, Eohilia |
| Amgen INC. | $373.64 | 2022-2025 | Tezspire, Actimmune |
| Biocryst US Sales Co., LLC | $310.88 | 2021-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $195.22 | 2025 | Neffy |
| Abbott Laboratories | $130.24 | 2019 | |
| Abiomed | $105.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $83.20 | 2022 | |
| Abbvie INC. | $80.25 | 2022-2023 | Rinvoq |
| Blueprint Medicines Corporation | $80.03 | 2021-2023 | |
| Ionis Pharmaceuticals, INC. | $78.81 | 2025 | Dawnzera |
| Lilly USA, LLC | $63.28 | 2025 | Ebglyss |
| Horizon Therapeutics Plc | $59.88 | 2020-2023 | Actimmune |
| Genentech USA, INC. | $54.83 | 2019-2025 | Xolair |
| Kaleo, INC. | $53.18 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $50.00 | 2020 | |
| Aimmune Therapeutics, INC. | $43.71 | 2020 | |
| Merck Sharp & Dohme LLC | $43.04 | 2025 | Capvaxive, Enflonsia |
| Invivyd INC | $42.41 | 2025 | Pemgarda |
| Grifols USA, LLC | $40.22 | 2019-2021 | |
| Incyte Corporation | $29.94 | 2025 | Opzelura |
| Verona Pharma, INC. | $29.19 | 2025 | Ohtuvayre |
| Adma Biomanufacturing LLC | $25.80 | 2025 | |
| Kedrion Biopharma, INC. | $24.25 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Arcutis Biotherapeutics, INC. | $18.38 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $17.21 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Cardona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.